Seattle Genetics, Inc. (NASDAQ:SGEN) EVP Darren S. Cline sold 5,024 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $51.94, for a total transaction of $260,946.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Darren S. Cline also recently made the following trade(s):

  • On Thursday, August 31st, Darren S. Cline sold 7,569 shares of Seattle Genetics stock. The shares were sold at an average price of $52.51, for a total value of $397,448.19.
  • On Monday, August 28th, Darren S. Cline sold 1,788 shares of Seattle Genetics stock. The shares were sold at an average price of $47.89, for a total value of $85,627.32.
  • On Monday, August 7th, Darren S. Cline sold 6,000 shares of Seattle Genetics stock. The shares were sold at an average price of $49.19, for a total value of $295,140.00.

Shares of Seattle Genetics, Inc. (SGEN) traded down 2.21% during midday trading on Friday, hitting $52.99. The stock had a trading volume of 865,122 shares. The firm’s market cap is $7.58 billion. The stock’s 50 day moving average price is $49.79 and its 200 day moving average price is $59.61. Seattle Genetics, Inc. has a 12 month low of $45.31 and a 12 month high of $75.36.

Seattle Genetics (NASDAQ:SGEN) last posted its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($0.39) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.03. Seattle Genetics had a negative return on equity of 38.42% and a negative net margin of 52.08%. The firm had revenue of $108.20 million for the quarter, compared to analysts’ expectations of $105.92 million. During the same period in the previous year, the firm earned ($0.23) EPS. The business’s quarterly revenue was up 13.4% on a year-over-year basis. On average, equities analysts forecast that Seattle Genetics, Inc. will post ($1.69) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Seattle Genetics, Inc. (SGEN) EVP Sells 5,024 Shares of Stock” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/08/insider-selling-seattle-genetics-inc-sgen-evp-sells-5024-shares-of-stock.html.

Several hedge funds have recently bought and sold shares of the company. Neuberger Berman Group LLC lifted its position in shares of Seattle Genetics by 0.5% during the 1st quarter. Neuberger Berman Group LLC now owns 12,630 shares of the biotechnology company’s stock valued at $794,000 after buying an additional 59 shares in the last quarter. Aperio Group LLC lifted its position in shares of Seattle Genetics by 0.3% during the 2nd quarter. Aperio Group LLC now owns 31,693 shares of the biotechnology company’s stock valued at $1,640,000 after buying an additional 91 shares in the last quarter. Eqis Capital Management Inc. lifted its position in shares of Seattle Genetics by 0.7% during the 2nd quarter. Eqis Capital Management Inc. now owns 26,258 shares of the biotechnology company’s stock valued at $1,359,000 after buying an additional 177 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in shares of Seattle Genetics by 1.2% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 15,613 shares of the biotechnology company’s stock valued at $981,000 after buying an additional 191 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its position in shares of Seattle Genetics by 1.1% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 18,400 shares of the biotechnology company’s stock valued at $952,000 after buying an additional 200 shares in the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages recently issued reports on SGEN. Cann restated a “hold” rating on shares of Seattle Genetics in a research note on Friday. Oppenheimer Holdings Inc. restated a “hold” rating on shares of Seattle Genetics in a research note on Saturday, June 3rd. Cantor Fitzgerald set a $46.00 price objective on Seattle Genetics and gave the company a “hold” rating in a research note on Wednesday, August 16th. ValuEngine upgraded Seattle Genetics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Cowen and Company set a $61.00 price objective on Seattle Genetics and gave the company a “hold” rating in a research note on Tuesday, June 6th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Seattle Genetics has a consensus rating of “Hold” and a consensus price target of $62.29.

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.